Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2024 06:31 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.